Gara Jalqabaatti › Lymphoma Selii Mantle › California

Qorannoo klinikaalii Lymphoma Selii Mantle California keessatti

Qorannoo 29 Lymphoma Selii Mantle f California keessatti hirmaatuu jiru.

Magaalota California keessatti

Takkalaa qorannoo (Ingiliffa)

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Tower Cancer Research Foundation, Beverly Hills
Cedars-Sinai Medical Center, Los Angeles

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 60 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT05976763

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

University of California, Davis, Davis
University of California, Los Angeles, Los Angeles
University of California, San Diego, San Diego
fi 1 dabalataa

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06252675

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, La Jolla

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT06542250

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Ucsf Fresno, Fresno
Kaiser Permanente Southern California, Irvine

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06742996

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
Stanford Medicine, Palo Alto
UCLA Santa Monica Cancer Care, Santa Monica

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05006716

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Stanford Cancer Center, Stanford

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT06553872

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

City of Hope, Duarte

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07101328

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

City of Hope Comprehensive Cancer Center, Duarte

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT07003295

A Study of ARC-02 in B-cell NHL

Start Cala, Los Angeles

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 26-Hag-2026 · NCT07691606

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 12-Hag-2026 · NCT06340737

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Cedars-Sinai Medical Center, Los Angeles

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 hanga 85 · Saalaa hunda · Haaromfame 10-Hag-2026 · NCT05887167

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 13 hanga 90 · Saalaa hunda · Haaromfame 06-Hag-2026 · NCT06533579

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center, Duarte

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Hag-2026 · NCT06675123

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

START Los Angele, Los Angeles

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT07424833

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

City of Hope, Duarte

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ado-2026 · NCT07121946

DALY II USA/ MB-CART2019.1 for DLBCL

UC San Diego Health, La Jolla
Stanford University, Stanford

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Ado-2026 · NCT04792489

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte
University of California, San Francisco, San Francisco

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ado-2026 · NCT05131022

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Wax-2026 · NCT04545762

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

City of Hope Medical center, Duarte

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Elb-2026 · NCT03523975

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Elb-2026 · NCT06859008

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

City of Hope, Duarte
Los Angeles Cancer Network, Los Angeles
UCLA Medical Center of Hematology/Oncology, Los Angeles
fi 1 dabalataa

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 12 hanga 95 · Saalaa hunda · Haaromfame 15-Elb-2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Bit-2026 · NCT04830137

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT06572618

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Gur-2026 · NCT05432635

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center, Duarte

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Ama-2026 · NCT06054776

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

UC Irvine Health, Orange

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Mud-2025 · NCT05602363

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

City of Hope Medical Center, Duarte
Stanford University, Stanford

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Sad-2025 · NCT05370430

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Duarte
Massive Bio SYNERGY-AI site, Irvine
Massive Bio SYNERGY-AI site, La Jolla
fi 3 dabalataa

Namoota walitti qabaa jiraQorannoo ilaalaa

Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Stanford Cancer Center, Palo Alto

Namoota walitti qabaa jiraQorannoo ilaalaa

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Hag-2024 · NCT05255354

Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.